HanAll Biopharma and Harbour Biomed Sign Collaboration and License Agreement for Development of Therapies in Greater China
September 12, 2017 at 01:22 pm EDT
Share
HanAll Biopharma has entered into a strategic collaboration and licence agreement with Harbour BioMed for the development, manufacturing and commercialization of two of HanAll's novel biologics in Greater China (including Hong Kong, Macau and Taiwan). The biologics include the anti-FcRn monoclonal antibody, HL161, for the treatment of pathogenic igG-mediated autoimmune diseases, and the anti-TNF ophthalmic solution, HL036, for dry eye and other inflammatory diseases. Under the terms of the agreement, HanAll will receive up to USD 81 million in total upfront, development, registration and sales milestones, as well as royalties on net sales. HanAll will continue to have the rights outside of Greater China.
Hanall Biopharma Co Ltd is a Korea-based company principally engaged in the manufacture and distribution of synthetic pharmaceuticals and biopharmaceuticals. The Company mainly manufactures and sells pharmaceutical products including antidiabetic drugs, skin drugs, muscle relaxants, hepatitis drugs, digestion drugs, anti-cardiovascular drugs, neurologic drugs, interferons, antiviral drugs, antibiotics, antihistamine, anti-inflammatory drugs, and others. The Company also engages in the leasing of real estates. The Company distributes its products in domestic and overseas markets.